Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Sees Large Decline in Short Interest

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) saw a large drop in short interest in December. As of December 15th, there was short interest totalling 1,180,000 shares, a drop of 21.3% from the November 30th total of 1,500,000 shares. Based on an average daily trading volume, of 16,290,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 4.5% of the shares of the company are short sold.

Insider Buying and Selling

In related news, insider Neal Flomenberg sold 1,078,600 shares of the stock in a transaction that occurred on Thursday, October 17th. The shares were sold at an average price of $1.62, for a total transaction of $1,747,332.00. Following the transaction, the insider now owns 4,254,302 shares in the company, valued at $6,891,969.24. This represents a 20.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 56.60% of the stock is owned by corporate insiders.

Institutional Trading of Tevogen Bio

A hedge fund recently bought a new stake in Tevogen Bio stock. HGC Investment Management Inc. bought a new position in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 223,077 shares of the company’s stock, valued at approximately $82,000. HGC Investment Management Inc. owned about 0.13% of Tevogen Bio as of its most recent filing with the Securities and Exchange Commission (SEC).

Tevogen Bio Trading Down 1.9 %

Shares of TVGN opened at $1.03 on Friday. The firm has a fifty day simple moving average of $1.49 and a two-hundred day simple moving average of $0.93. Tevogen Bio has a 1-year low of $0.26 and a 1-year high of $21.09.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.